Arcus Biosciences Shares Outstanding History (RCUS)
Arcus Biosciences reported 125.3M shares outstanding at the end of fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 125.3M | 33.1M | +35.90% |
| 2024 | 2024-12-31 | 92.2M | 16.7M | +22.12% |
| 2023 | 2023-12-31 | 75.5M | 2.6M | +3.57% |
| 2022 | 2022-12-31 | 72.9M | 2.1M | +2.97% |
| 2021 | 2021-12-31 | 70.8M | 5.7M | +8.73% |
| 2020 | 2020-12-31 | 65.1M | 19.2M | +41.78% |
| 2019 | 2019-12-31 | 45.9M | 1.4M | +3.11% |
| 2018 | 2018-12-31 | 44.5M | 40.4M | +988.71% |
| 2017 | 2017-12-31 | 4.1M | — | — |
Arcus Biosciences quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 127.0M | 20.6M | +19.36% |
| Q1 2026 | 2026-03-31 | 125.5M | 19.6M | +18.51% |
| Q4 2025 | 2025-12-31 | 125.3M | 33.1M | +35.90% |
| Q3 2025 | 2025-09-30 | 107.1M | 15.6M | +17.05% |
| Q2 2025 | 2025-06-30 | 106.4M | 15.1M | +16.54% |
| Q1 2025 | 2025-03-31 | 105.9M | 15.0M | +16.50% |
| Q4 2024 | 2024-12-31 | 92.2M | 16.7M | +22.12% |
| Q3 2024 | 2024-09-30 | 91.5M | 16.7M | +22.33% |
| Q2 2024 | 2024-06-30 | 91.3M | 16.8M | +22.55% |
| Q1 2024 | 2024-03-31 | 90.9M | 17.8M | +24.35% |
| Q4 2023 | 2023-12-31 | 75.5M | 2.6M | +3.57% |
| Q3 2023 | 2023-09-30 | 74.8M | 2.4M | +3.38% |
| Q2 2023 | 2023-06-30 | 74.5M | 2.4M | +3.35% |
| Q1 2023 | 2023-03-31 | 73.1M | 1.5M | +2.06% |
| Q4 2022 | 2022-12-31 | 72.9M | 2.1M | +2.99% |
| Q3 2022 | 2022-09-30 | 72.4M | 2.1M | +3.01% |
| Q2 2022 | 2022-06-30 | 72.1M | 711,414 | +1.00% |
| Q1 2022 | 2022-03-31 | 71.6M | 656,800 | +0.93% |
| Q4 2021 | 2021-12-31 | 70.8M | 5.7M | +8.70% |
| Q3 2021 | 2021-09-30 | 70.2M | 5.3M | +8.19% |
| Q2 2021 | 2021-06-30 | 71.4M | 12.4M | +21.09% |
| Q1 2021 | 2021-03-31 | 71.0M | 25.0M | +54.33% |
| Q4 2020 | 2020-12-31 | 65.1M | 19.2M | +41.78% |
| Q3 2020 | 2020-09-30 | 64.9M | 19.1M | +41.62% |
| Q2 2020 | 2020-06-30 | 58.9M | 13.1M | +28.54% |
| Q1 2020 | 2020-03-31 | 46.0M | 1.4M | +3.25% |
| Q4 2019 | 2019-12-31 | 45.9M | 1.4M | +3.11% |
| Q3 2019 | 2019-09-30 | 45.8M | 1.4M | +3.13% |
| Q2 2019 | 2019-06-30 | 45.9M | 1.4M | +3.14% |
| Q1 2019 | 2019-03-31 | 44.5M | 80,319 | +0.18% |
| Q4 2018 | 2018-12-31 | 44.5M | 40.4M | +988.71% |
| Q3 2018 | 2018-09-30 | 44.5M | — | — |
| Q2 2018 | 2018-06-30 | 44.5M | — | — |
| Q1 2018 | 2018-03-31 | 44.5M | — | — |
| Q4 2017 | 2017-12-31 | 4.1M | — | — |
Arcus Biosciences shares outstanding trends
Over the last five reported fiscal years, Arcus Biosciences's shares outstanding moved from 65.1M to 125.3M, a change of 60.2M. The latest reported quarter, Q2 2026, shows 127.0M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences filings at SEC.gov ↗